Cancer diagnosis & prognosis最新文献

{"title":"Outcomes of Combined Atezolizumab Plus Chemotherapy in Non-small Cell Lung Cancer Patients in Clinical Practice.","authors":"Takeshi Numata, Ryota Nakamura, Toshihiro Shiozawa, Hiroko Watanabe, Shinichiro Okauchi, Gen Ogara, Tomohiro Tamura, Norihiro Kikuchi, Kunihiko Miyazaki, Shigen Hayashi, Takaaki Yamashita, Koichi Kurishima, Masaharu Inagaki, Hiroaki Satoh, Takayuki Kaburagi, Takeo Endo, Nobuyuki Hizawa","doi":"10.21873/cdp.10418","DOIUrl":"https://doi.org/10.21873/cdp.10418","url":null,"abstract":"<p><strong>Background/aim: </strong>Atezolizumab, one of the anti-PD-L1 antibodies, targets PD-L1 expressed on cancer cells and antigen-presenting cells. This immune checkpoint inhibitor is now commonly used in combination with chemotherapy. The objectives of this study were to confirm the treatment outcomes of combined atezolizumab plus chemotherapy, and to identify prognostic factors, with a particular focus on the impact of the site of metastasis in real-world clinical practice.</p><p><strong>Patients and methods: </strong>A retrospective review of clinical information on non-small cell lung cancer patients who received combined atezolizumab plus chemotherapy from May 2018 to August 2024 at our 11 hospitals was conducted.</p><p><strong>Results: </strong>The 141 patients evaluated had a median progression-free survival of 8.0 months and a median overall survival of 19.0 months. Multivariate analyses showed that 'absence of liver metastases', 'absence of adrenal metastases', 'first-line combined atezolizumab plus chemotherapy', and 'good performance status' were associated with progression-free survival and overall survival. Immune-related adverse events were observed in 27.7% of patients, with grade 3 or higher in 9.9% of patients, and grade 5 in 2.1% of patients.</p><p><strong>Conclusion: </strong>Efficacy and immune-related adverse events associated with the combination of atezolizumab and chemotherapy in non-small cell lung cancer patients were comparable to previous clinical trials. To ensure that appropriate patients receive the most effective treatment, it is important to identify detailed prognostic factors, including clinical information, such as the affected metastatic organs. Continued research and further accumulation of knowledge in this area are eagerly anticipated.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"5 1","pages":"105-114"},"PeriodicalIF":0.0,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11696331/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Significance of Lymphocyte-to-Monocyte Ratio in Patients With Unresectable Biliary Tract Cancer Undergoing Systemic Chemotherapy.","authors":"Hideo Suzuki, Akifumi Kuwano, Junro Takahira, Kosuke Tanaka, Masayoshi Yada, Kenta Motomura","doi":"10.21873/cdp.10422","DOIUrl":"https://doi.org/10.21873/cdp.10422","url":null,"abstract":"<p><strong>Background/aim: </strong>The incidence of biliary tract cancers (BTC), including cholangiocarcinoma and gallbladder cancer, has been increasing worldwide. Approximately 70% of BTC patients have advanced disease at diagnosis, leading to a poor survival rate. Recent clinical trials have demonstrated that the addition of immune checkpoint inhibitors, such as durvalumab or pembrolizumab, to gemcitabine plus cisplatin chemotherapy significantly improves survival rates, making triple therapy the current standard for first-line treatment of BTC. Few models with predictive value exist for BTC. Lymphocyte-to-monocyte ratio (LMR) is a relatively new inflammation-related score and translational biomarker and has prognostic value for survival of patients with other cancers. This study assessed the prognostic value of LMR in patients with advanced BTC and analyzed the risk factors associated with overall survival (OS).</p><p><strong>Patients and methods: </strong>This prospective study enrolled 75 patients with advanced BTC who were treated with gemcitabine-based chemotherapies at Aso Iizuka Hospital, Japan. The cutoff value of LMR for predicting 6-month survival was 3.27.</p><p><strong>Results: </strong>OS was longer for patients with high LMR compared with low LMR (median 32.4 months and 8.6 months, respectively; p=0.0069). Multivariate analysis identified LMR >3.27 [hazard ratio (HR)=0.427, p=0.0339] and objective response rate (HR=0.210, p=0.0116) as independent factors associated with OS.</p><p><strong>Conclusion: </strong>Despite some limitations, such as the single-center design and small sample size, the results of this study suggest a potential role for LMR in predicting survival outcomes for BTC patients treated with gemcitabine-based chemotherapies.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"5 1","pages":"132-137"},"PeriodicalIF":0.0,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11696337/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complete Response (CR) in a Previously-progressing Chronic Lymphocytic Leukemia (CLL) Patient Treated With Methionine Restriction in Combination With First-line Chemotherapy.","authors":"Sei Morinaga, Qinghong Han, Kohei Mizuta, Byung Mo Kang, Norio Yamamoto, Katsuhiro Hayashi, Hiroaki Kimura, Shinji Miwa, Kentaro Igarashi, Takashi Higuchi, Hiroyuki Tsuchiya, Satoru Demura, Robert M Hoffman","doi":"10.21873/cdp.10407","DOIUrl":"https://doi.org/10.21873/cdp.10407","url":null,"abstract":"<p><strong>Background/aim: </strong>Chronic lymphocytic leukemia (CLL) is currently incurable. CLL is characterized by disordered DNA methylation. The aim of the present study was to target methylation with methionine restriction in a patient with progressive CLL.</p><p><strong>Case report: </strong>Methionine restriction for the patient was achieved with a low-methionine vegan diet and oral recombinant methioninase (o-rMETase). The patient also received rituximab, once per week for four weeks, and acalabrutinib 100 mg, twice daily (bid) continuously. The patient's white blood cell count decreased by 95% from peak levels and extensive lymphadenopathy disappeared during combination treatment with o-rMETase, rituximab, and acalabrutinib.</p><p><strong>Conclusion: </strong>The combination of methionine restriction and first-line chemotherapy resulted in an apparent complete response (CR) in a CLL patient, a rare event. The duration of the CR will be monitored, and additional CLL patients will be treated similarly in the future.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"5 1","pages":"21-26"},"PeriodicalIF":0.0,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11696344/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current Status of Sequential Treatment for Castration-resistant Prostate Cancer: A Retrospective Analysis.","authors":"Kazuhiko Oshinomi, Toshiki Mugita, Tatsuki Inoue, Madoka Omizu, Motoki Yamagishi, Yoshihiro Nakagami, Masakazu Nagata, Hideaki Shimoyama, Michiya Ota, Jun Morita, Haruaki Sasaki, Eiji Matsubara, Katsuyuki Saito, Kohzo Fuji, Masashi Morita, Takashi Fukagai","doi":"10.21873/cdp.10412","DOIUrl":"https://doi.org/10.21873/cdp.10412","url":null,"abstract":"<p><strong>Background/aim: </strong>Although multiple treatments are available for metastatic castration-resistant prostate cancer, data to determine the optimal treatment sequence are limited. This study aimed to investigate the current status of drug therapy for castration-resistant prostate cancer and clarify the sequential treatment in actual clinical practice.</p><p><strong>Patients and methods: </strong>This retrospective study included 425 patients diagnosed with castration-resistant prostate cancer at Showa University Hospital and affiliated hospitals between January 2014 and December 2021, who were treated with any of the following four drugs: novel androgen receptor signal inhibitors (abiraterone acetate and enzalutamide) and anticancer drugs (docetaxel and cabazitaxel). We investigated the actual treatment choices for castration-resistant prostate cancer, focusing on the order of administration of the four drugs. This analysis was visualized using a Sankey diagram.</p><p><strong>Results: </strong>Regarding the number of drugs administered, most patients received one type of drug, with androgen receptor signal inhibitors being the most commonly administered (total, 179; enzalutamide, 139 and abiraterone acetate, 40). Enzalutamide was the most frequently selected first-line drug (58.4%). The most common sequence for second-line treatment was androgen receptor signal inhibitor-androgen receptor signal inhibitor (n=96), followed by androgen receptor signal inhibitor-docetaxel (n=85), docetaxel-androgen receptor signal inhibitor (n=59), and docetaxel-cabazitaxel (n=6).</p><p><strong>Conclusion: </strong>Androgen receptor signal inhibitors is the most commonly used drug category for first-line treatment of castration-resistant prostate cancer, with enzalutamide being the most commonly used drug. Further investigations are required regarding patient background and prognosis.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"5 1","pages":"56-61"},"PeriodicalIF":0.0,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11696339/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Value of the Modified Cachexia Index in Colorectal Cancer Patients Undergoing Curative Surgery.","authors":"Tsuyoshi Nishiyama, Masatsune Shibutani, Hideki Tanda, Yuki Seki, Shinichiro Kashiwagi, Hiroaki Kasashima, Tatsunari Fukuoka, Kiyoshi Maeda","doi":"10.21873/cdp.10416","DOIUrl":"https://doi.org/10.21873/cdp.10416","url":null,"abstract":"<p><strong>Background/aim: </strong>The cachexia index (CXI) has been reported to be a useful indicator for predicting the prognosis of cancer patients. However, CXI calculation requires skeletal muscle index (SMI) measurements, which involves an analysis of computed tomography images using an imaging software program, which makes the calculation process highly complex and time-consuming. Recently, the modified cachexia index (mCXI), calculated using the urea-to-creatinine ratio (UCR) instead of SMI, has been reported to be a useful marker that is easier to calculate than CXI. This study aimed to evaluate the correlation between mCXI and the prognosis of patients with colorectal cancer (CRC).</p><p><strong>Patients and methods: </strong>A total of 291 patients who underwent curative surgery for stage I-III CRC were enrolled. mCXI was calculated as the serum albumin concentration/neutrophil-to-lymphocyte ratio (NLR)/UCR. A receiver operating characteristic (ROC) curve analysis was used to determine the optimal cutoff value of the mCXI for predicting prognosis.</p><p><strong>Results: </strong>The median mCXI was 0.089 (range=0.012-0.354). The ROC curve analysis revealed that the appropriate cut-off value for mCXI was 0.113. The low mCXI group had significantly shorter relapse-free and overall survival rates than the high mCXI group (p=0.030 and p=0.014, respectively).</p><p><strong>Conclusion: </strong>mCXI, which does not require an image analysis, may be closely associated with prognosis in patients undergoing curative surgery for CRC.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"5 1","pages":"89-94"},"PeriodicalIF":0.0,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11696332/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Pretreatment Albumin-bilirubin Grade With Hepatotoxicity and Efficacy in EGFR-TKIs Therapy for NSCLC.","authors":"Hiroki Arihara, Hidetsugu Nagamatsu, Yuji Hayakawa, Hiroki Mase, Tomoyuki Araya, Toshiyuki Kita","doi":"10.21873/cdp.10417","DOIUrl":"https://doi.org/10.21873/cdp.10417","url":null,"abstract":"<p><strong>Background/aim: </strong>The albumin-bilirubin (ALBI) grade is an assessment tool for hepatic function and prognosis in patients with hepatocellular carcinoma (HCC). However, its significance in patients with non-small cell lung cancer (NSCLC) treated with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) remains unclear. We retrospectively investigated the relationship between pre-treatment ALBI grade and hepatotoxicity and treatment efficacy in patients with NSCLC receiving EGFR-TKIs.</p><p><strong>Patients and methods: </strong>We analyzed data from 182 patients with NSCLC treated with EGFR-TKIs. Patients were categorized into ALBI grades 1/2a and 2b/3 groups. We examined the association between ALBI grade, hepatotoxicity, and time to treatment failure (TTF) using univariate and multivariate analyses.</p><p><strong>Results: </strong>In the univariate Kaplan-Meier analysis, ALBI grade was not associated with hepatotoxicity (log-rank p=0.56). This finding was consistent with the multivariate analysis of patients treated with gefitinib and erlotinib (n=158). However, In the univariate Kaplan-Meier analysis, the median TTF for the ALBI grade 1/2a group was 10.6 months, compared to 5.8 months for the ALBI grade 2b/3 group (hazard ratio=1.66, 95% confidence interval=1.19-2.33, p=0.003). Multivariate analysis confirmed that ALBI grade 2b/3 (hazard ratio=1.64, 95% confidence interval=1.16-2.30, p<0.01) was independently associated with shortened TTF.</p><p><strong>Conclusion: </strong>Pretreatment ALBI grade classification can predict efficacy in patients with NSCLC treated with EGFR-TKIs.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"5 1","pages":"95-104"},"PeriodicalIF":0.0,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11696340/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of C-FOS/C-JUN Transcriptional Factors Co-Expression in Non-small Cell Lung Carcinoma.","authors":"Konstantinos Manios, Aristeidis Chrysovergis, Vasileios Papanikolaou, Evangelos Tsiambas, Maria Adamopoulou, Athanasios Stamatelopoulos, Κonstantinos Vachlas, Sotirios Papouliakos, Pavlos Pantos, George Agrogiannis, Andreas C Lazaris, Efthymios Kyrodimos, Periklis Tomos, Nikolaos Kavantzas","doi":"10.21873/cdp.10406","DOIUrl":"https://doi.org/10.21873/cdp.10406","url":null,"abstract":"<p><strong>Background/aim: </strong>Significant transcription factors - including c-Fos (gene locus: 14q24.3) and c-Jun (gene locus: 1p32-p31) - regulate cell homeostasis preventing abnormal signal transduction to nucleus. Their over-activation seems to be associated with an aggressive phenotype in non-small cell lung carcinomas (NSCLCs). In the current study, our aim was to co-analyze c-FOS/c-JUN protein expression in a series of NSCLCs correlating them to the corresponding clinico-pathological features.</p><p><strong>Materials and methods: </strong>A set of fifty (n=50) paraffin embedded NSCLC tissue sections were selected comprising of adenocarcinomas (n=25) and squamous cell carcinomas (n=25), respectively. Immunocytochemistry (IHC) for the c-FOS/c-JUN markers was implemented. Digital image analysis (DIA) was also performed for evaluating objectively the corresponding immunostaining intensity levels of the examined proteins.</p><p><strong>Results: </strong>All the examined tissue samples expressed the markers in different protein levels. High staining intensity levels were detected in 34/50 (68%) and 24/50 (48%), respectively. C-FOS over expression was statistically significant correlated to stage (p=0.033), whereas C-JUN over expression was associated with NSCLC histotype (p=0.05) and with maximum tumor diameter (p=0.046).</p><p><strong>Conclusion: </strong>C-FOS/C-JUN co- over activation is observed frequently in NSCLC, playing potentially a central role in the aggressiveness of the malignancy's phenotype (advanced stage, increased metastatic potential). Development and implementation of novel agents that target these transcription factors is a promising approach for applying targeted therapeutic strategies in NSCC patients based on specific genetic signatures and protein profiles.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"5 1","pages":"15-20"},"PeriodicalIF":0.0,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11696338/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Changes in Psoas Muscle Index on Prognosis in Patients With Colorectal Liver Metastases.","authors":"Yukina Kusunoki, Tatsunari Fukuoka, Atsushi Sugimoto, Gen Tsujio, Ken Yonemitsu, Yuki Seki, Hiroaki Kasashima, Masatsune Shibutani, Kiyoshi Maeda","doi":"10.21873/cdp.10414","DOIUrl":"https://doi.org/10.21873/cdp.10414","url":null,"abstract":"<p><strong>Background/aim: </strong>Reduction in skeletal muscle mass during chemotherapy is associated with poor outcomes. This study investigated the impact of changes in the psoas muscle index (PMI) on the prognosis of patients with unresectable colorectal liver metastases (CRLM) undergoing chemotherapy, including subgroup analyses based on the initial treatment response assessment.</p><p><strong>Patients and methods: </strong>We evaluated 47 patients with unresectable CRLM who underwent systematic chemotherapy and assessed changes in PMI to determine their prognosis.</p><p><strong>Results: </strong>Changes in PMI were significantly associated with the presence or absence of primary tumor resection and the chemotherapeutic responses to first-line chemotherapy. The PMI reduction group was significantly associated with poor prognosis in both overall survival (OS) and progression-free survival (PFS) in patients with CRLM, and in both OS and PFS in the partial response (PR) group at the initial chemotherapy response assessment.</p><p><strong>Conclusion: </strong>Skeletal muscle loss at chemotherapy initiation was significantly associated with poorer survival in patients with unresectable CRLM. Maintaining muscle mass could serve as a new indicator for identifying patients with a PR at the initial chemotherapy response assessment for prognosis. Personalized interventions should be investigated to determine whether they can improve muscle mass and lead to better clinical outcomes.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"5 1","pages":"72-82"},"PeriodicalIF":0.0,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11696330/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Global Immune-Nutrition-Information Index (GINI) Is an Independent Prognostic Factor for Esophageal Cancer Patients Who Receive Curative Treatment.","authors":"Sosuke Yamamoto, Toru Aoyama, Yukio Maezawa, Itaru Hashimoto, Ryuki Esashi, Keisuke Kazama, Koji Numata, Mamoru Uchiyama, Ayako Tamagawa, Aya Saito, Norio Yukawa","doi":"10.21873/cdp.10419","DOIUrl":"https://doi.org/10.21873/cdp.10419","url":null,"abstract":"<p><strong>Background/aim: </strong>The aim of the present study was to evaluate the clinical impact of the Global Immune-Nutrition-Information Index (GINI) in patients with esophageal cancer (EC) who received curative treatment and to clarify the potential of the GINI as a prognostic factor.</p><p><strong>Patients and methods: </strong>Patients who underwent curative resection for EC at Yokohama City University between 2000 and 2020 were consecutively chosen based on their medical records. The GINI was defined as follows: GINI=[C-reactive protein×platelet×monocyte×neutrophil]/[albumin×lymphocyte].</p><p><strong>Results: </strong>This study included 180 patients. Among them, 67 were categorized into the GINI-low group and 113 were categorized into the GINI-high group, with a cutoff value of 5000. The 3- and 5- year overall survival (OS) rates were 75.6% and 64.9%, respectively, in the GINI-low group and 55.3% and 48.1% in the GINI-high group (p=0.005). According to a multivariate analysis for OS, the GINI was identified as an independent prognostic factor [hazard ratio=2.106, 95% confidence interval=1.252-3.544, p=0.005]. Similar results were observed for RFS. In addition, the GINI affects preoperative tube feeding and the induction rate of neoadjuvant chemotherapy (NAC).</p><p><strong>Conclusion: </strong>The GINI is a promising biomarker for the treatment and management of EC.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"5 1","pages":"115-121"},"PeriodicalIF":0.0,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11696334/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Outcomes of Micropapillary Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy.","authors":"Kazumasa Jojima, Akinori Minato, Hirotsugu Noguchi, Yojiro Tsuda, Naohiro Fujimoto","doi":"10.21873/cdp.10420","DOIUrl":"https://doi.org/10.21873/cdp.10420","url":null,"abstract":"<p><strong>Background/aim: </strong>This study examined the treatment outcomes of radical cystectomy (RC) for micropapillary subtype (MPS) bladder cancer treated at our hospital.</p><p><strong>Patients and methods: </strong>Histopathological findings of RC specimens collected from 2003 to 2020 were evaluated. Recurrence-free survival (RFS) and overall survival (OS) after RC, as well as the efficacy of chemotherapy in cases of recurrence, were retrospectively assessed.</p><p><strong>Results: </strong>Of 202 patients who underwent RC, seven (3.4%) had MPS bladder cancer. All seven patients underwent immediate RC without neoadjuvant chemotherapy. The median patient age was 58 years (range=52-71 years), and all patients were male. After RC, median RFS was 14 months (range=6-115 months), and median OS was 31 months (range=18-115 months). The clinical tumor stage was cT1 or lower in two patients (28.5%), cT2 in two patients (28.5%), and cT3 or higher in three patients (42.8%). No preoperative lymph node metastasis was observed. The pathological tumor stage was pT1 or lower in one patient (14.2%), pT2 in one patient (14.2%), and pT3 or higher in five patients (71.4%). The pathological lymph node stage was observed in five patients (71.4%). Although six of seven patients (85.7%) received adjuvant chemotherapy, all patients experienced relapse. The objective response rates of primary and secondary chemotherapy at relapse were both 33%. One patient received immune checkpoint inhibitor therapy and maintained stable disease for 12 months.</p><p><strong>Conclusion: </strong>The recurrence rate after RC for MPS bladder cancer was high, and prognosis was poor.</p>","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"5 1","pages":"122-126"},"PeriodicalIF":0.0,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11696342/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}